A share price of Ideaya Biosciences Inc [IDYA] is currently trading at $40.65, up 1.78%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IDYA shares have gain 8.14% over the last week, with a monthly amount drifted -7.36%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ideaya Biosciences Inc [NASDAQ: IDYA] stock has seen the most recent analyst activity on March 08, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $55. Previously, SVB Securities started tracking the stock with Outperform rating on August 08, 2023, and set its price target to $33. On May 24, 2023, Goldman initiated with a Buy rating and assigned a price target of $32 on the stock. Stifel upgraded its rating to a Buy and increased its price target to $24 on April 24, 2023. Berenberg initiated its recommendation with a Buy and recommended $26 as its price target on March 23, 2023. RBC Capital Mkts started tracking with a Outperform rating for this stock on February 28, 2023, and assigned it a price target of $25. In a note dated December 28, 2022, CapitalOne initiated an Overweight rating and provided a target price of $29 on this stock.
Ideaya Biosciences Inc experienced fluctuations in its stock price throughout the past year between $18.11 and $47.74. Currently, Wall Street analysts expect the stock to reach $24.75 within the next 12 months. Ideaya Biosciences Inc [NASDAQ: IDYA] shares were valued at $40.65 at the most recent close of the market. An investor can expect a potential drop of -39.11% based on the average IDYA price forecast.
Analyzing the IDYA fundamentals
Trailing Twelve Months sales for Ideaya Biosciences Inc [NASDAQ:IDYA] were 23.39M which represents -2.46% decline. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -5.75%, Pretax Profit Margin comes in at -4.83%, and Net Profit Margin reading is -4.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.22 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 39.96 points at the first support level, and at 39.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.36, and for the 2nd resistance point, it is at 42.07.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ideaya Biosciences Inc [NASDAQ:IDYA] is 19.65. As well, the Quick Ratio is 19.65, while the Cash Ratio is 5.79. Considering the valuation of this stock, the price to sales ratio is 129.93, the price to book ratio is 4.26.
Transactions by insiders
Recent insider trading involved Hata Yujiro S, President and CEO, that happened on Feb 09 ’24 when 23557.0 shares were sold., Ruiz Briseno Andres completed a deal on Feb 09 ’24 to sell 2000.0 shares. Meanwhile, President and CEO Hata Yujiro S sold 75815.0 shares on Feb 08 ’24.
